• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测日本息肉状脉络膜血管病变患者光动力疗法治疗 1 年后视力结果的因素。

Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy.

机构信息

Ohtsuka Eye Hospital, Sapporo, Japan.

出版信息

Retina. 2011 May;31(5):857-65. doi: 10.1097/IAE.0b013e3181fecda9.

DOI:10.1097/IAE.0b013e3181fecda9
PMID:21124252
Abstract

PURPOSE

The purpose of this study was to determine the factors predictive of visual acuity (VA) outcomes 1 year after photodynamic therapy (PDT) for polypoidal choroidal vasculopathy.

METHODS

We prospectively studied 220 eyes of 210 Japanese patients with polypoidal choroidal vasculopathy treated with primary application of PDT. A stepwise logistic regression model was used to estimate the independent factors predictive of better VA and improvement of VA 1 year after the primary PDT.

RESULTS

Visual acuities at the various follow-up evaluations improved significantly compared with baseline (P = 0.001 for all comparisons). The VA improved and decreased more than 0.3 logarithm of minimum angle of resolution unit 1 year after the primary PDT in 55 (25%) and 21 (10%) eyes, respectively. Stepwise logistic regression analysis showed that younger age, smaller greatest linear dimension, better baseline VA, and less baseline hemorrhage were significant and independent factors predictive of better VA 1 year after PDT, and younger age, smaller greatest linear dimension, better baseline VA, less hemorrhaging, and the presence of a serous macular detachment at baseline were significant and independent factors predictive of VA improvement.

CONCLUSION

Photodynamic therapy stabilized eyes anatomically and functionally. Clinical characteristics at baseline were predictors of favorable VA outcomes after PDT. These findings may help establish the strategy of treatment for polypoidal choroidal vasculopathy.

摘要

目的

本研究旨在确定光动力疗法(PDT)治疗息肉状脉络膜血管病变 1 年后预测视力(VA)结果的相关因素。

方法

我们前瞻性研究了 210 例 220 只眼的日本息肉状脉络膜血管病变患者,这些患者均接受了原发性 PDT 治疗。采用逐步逻辑回归模型来评估预测原发性 PDT 治疗后 1 年 VA 更好和 VA 改善的独立因素。

结果

与基线相比,各随访评估时的视力均显著提高(所有比较的 P = 0.001)。在原发性 PDT 治疗后 1 年,VA 改善超过 0.3 个最小分辨角对数单位的眼分别有 55 只(25%)和 21 只(10%),VA 下降超过 0.3 个最小分辨角对数单位的眼分别有 14 只(6.7%)和 5 只(2.4%)。逐步逻辑回归分析显示,年龄较小、最大线性尺寸较小、基线 VA 较好和基线出血较少是 PDT 治疗后 1 年 VA 更好的重要且独立的预测因素,而年龄较小、最大线性尺寸较小、基线 VA 较好、出血较少和基线存在浆液性黄斑脱离是 VA 改善的重要且独立的预测因素。

结论

PDT 在解剖学和功能上稳定了眼睛。基线时的临床特征是 PDT 治疗后 VA 结果良好的预测因素。这些发现可能有助于确定息肉状脉络膜血管病变的治疗策略。

相似文献

1
Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy.预测日本息肉状脉络膜血管病变患者光动力疗法治疗 1 年后视力结果的因素。
Retina. 2011 May;31(5):857-65. doi: 10.1097/IAE.0b013e3181fecda9.
2
Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.影响光动力疗法治疗后一年息肉样脉络膜血管病变患者视力预后的因素。
Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1233-9. doi: 10.1007/s00417-010-1365-2. Epub 2010 Mar 30.
3
Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.少能量频域光动力疗法治疗息肉状脉络膜血管病变的两年结果。
Am J Ophthalmol. 2013 Jan;155(1):96-102.e1. doi: 10.1016/j.ajo.2012.06.027. Epub 2012 Sep 18.
4
Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.光动力疗法治疗息肉状脉络膜血管病变的 3 年随访结果。
Jpn J Ophthalmol. 2011 Jan;55(1):39-44. doi: 10.1007/s10384-010-0886-x. Epub 2011 Feb 18.
5
One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.减少强度的光动力疗法治疗息肉样脉络膜血管病变的一年疗效。
Am J Ophthalmol. 2010 Mar;149(3):465-71.e1. doi: 10.1016/j.ajo.2009.09.020. Epub 2009 Dec 30.
6
Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.光动力疗法联合玻璃体内注射雷珠单抗治疗息肉状脉络膜血管病变。
Am J Ophthalmol. 2012 Jan;153(1):68-80.e1. doi: 10.1016/j.ajo.2011.07.001. Epub 2011 Sep 9.
7
Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.眼内雷珠单抗联合或不联合光动力疗法治疗有症状的息肉状脉络膜血管病变。
Retina. 2011 Sep;31(8):1581-8. doi: 10.1097/IAE.0b013e31820d3f3f.
8
Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.玻璃体内注射贝伐单抗联合光动力疗法治疗息肉状脉络膜血管病变的疗效。
Am J Ophthalmol. 2010 Jul;150(1):48-54.e1. doi: 10.1016/j.ajo.2010.02.008.
9
Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.光动力疗法、雷珠单抗和雷珠单抗联合光动力疗法治疗息肉样脉络膜血管病变。
Retina. 2011 Mar;31(3):464-74. doi: 10.1097/IAE.0b013e3181f274ec.
10
Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.抗血管内皮生长因子药物联合光动力疗法治疗息肉状脉络膜血管病变的长期疗效和安全性。
Indian J Ophthalmol. 2018 Aug;66(8):1119-1127. doi: 10.4103/ijo.IJO_1222_17.

引用本文的文献

1
Efficacy of Initial vs. Delayed Photodynamic Therapy in Combination With Conbercept for Polypoidal Choroidal Vasculopathy.初治与延迟光动力疗法联合康柏西普治疗息肉样脉络膜血管病变的疗效
Front Med (Lausanne). 2022 Feb 9;8:791935. doi: 10.3389/fmed.2021.791935. eCollection 2021.
2
Real-world outcomes of combined therapy of photodynamic therapy with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.光动力疗法联合抗血管内皮生长因子治疗息肉状脉络膜血管病变的真实世界结局。
Eye (Lond). 2022 Oct;36(10):1934-1939. doi: 10.1038/s41433-021-01773-x. Epub 2021 Sep 28.
3
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy.
雷珠单抗对息肉状脉络膜血管病变患者的治疗效果。
BMC Ophthalmol. 2019 Jul 19;19(1):153. doi: 10.1186/s12886-019-1156-4.
4
Polypoidal choroidal vasculopathy: An update on current management and review of literature.息肉样脉络膜血管病变:当前治疗进展及文献综述
Taiwan J Ophthalmol. 2019 Apr-Jun;9(2):72-92. doi: 10.4103/tjo.tjo_35_18.
5
Polypoidal Choroidal Vasculopathy.息肉样脉络膜血管病变
Curr Ophthalmol Rep. 2017 Jun;5(2):176-186. doi: 10.1007/s40135-017-0137-0. Epub 2017 Apr 21.
6
Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review.光动力疗法联合雷珠单抗治疗息肉状脉络膜血管病变:2年结果及系统评价
Int J Ophthalmol. 2017 Mar 18;10(3):413-422. doi: 10.18240/ijo.2017.03.14. eCollection 2017.
7
Systemic steroids as an aid to the management of Idiopathic Polypoidal Choroidal Vasculopathy (IPCV): A descriptive analysis.全身用类固醇辅助治疗特发性息肉状脉络膜血管病变(IPCV):一项描述性分析。
Saudi J Ophthalmol. 2016 Jan-Mar;30(1):14-9. doi: 10.1016/j.sjopt.2015.08.001. Epub 2015 Aug 8.
8
Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.基线息肉大小作为息肉样脉络膜血管病变复发的潜在预测因素。
Graefes Arch Clin Exp Ophthalmol. 2016 Aug;254(8):1519-1527. doi: 10.1007/s00417-015-3241-6. Epub 2015 Dec 21.
9
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy.息肉状脉络膜血管病变按需治疗后第3年的个性化雷珠单抗治疗策略
BMC Ophthalmol. 2015 Apr 10;15:37. doi: 10.1186/s12886-015-0026-y.
10
Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.雷珠单抗联合光动力疗法治疗息肉状脉络膜血管病变1年的疗效及影响疗效的预测因素
Eye (Lond). 2014 Dec;28(12):1469-76. doi: 10.1038/eye.2014.222. Epub 2014 Sep 26.